Severe viral hepatitis B is a disease associated with significant morbidity and mortality.
Clinical controlled trials show that the efficacy of treatment of severe viral hepatitis B with glucocorticoids remains debatable.
Dr He Bing and colleagues performed a meta-analysis to evaluate the safety, efficacy, and side effects of glucocorticoid therapy for severe viral hepatitis B.
The researers searched PubMed, Medline, Embase, Cochrane Library, and Google Scholar for randomized-controlled trials published before 2012 in which glucocorticoid therapy was compared with routine treatment for severe viral hepatitis B.
The primary outcome was the survival rate of the two groups.
|Glucocorticoid treatment was not associated with bleeding |
|European Journal of Gastroenterology and Hepatology|
The team selected 8 controlled clinical trials, which included 597 patients.
The research team recorded a benefit of glucocorticoid treatment on the survival rate of patients with severe viral hepatitis B risk ratio.
The benefit was most noticeable in patients at the stage of preliver failure, whereas there was no efficacy for patients with liver failure.
Glucocorticoid treatment was not associated with the development of secondary infection and bleeding.
Dr Bing's team commented, "Treatment with glucocorticoids can significantly increase the survival rate of patients with severe hepatitis B"
"The benefit was most noticeable in patients at the stage of preliver failure."
"However, the incidence of secondary infection and bleeding did not change significantly."
"This finding suggests that prompt and timely glucocorticoid treatment is crucial."